Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
va-Q-tec AG specializes in high-performance thermal insulation and temperature-controlled packaging solutions, primarily serving the pharmaceutical and logistics sectors. Its proprietary phase change materials (PCMs) and vacuum insulation panels (VIPs) provide a competitive edge in maintaining temperature-sensitive products during transport, particularly in Europe and North America.
va-Q-tec generates revenue through the sale of its innovative thermal insulation products and temperature-controlled packaging solutions. The company benefits from strong pricing power due to its proprietary technologies and established relationships with major pharmaceutical companies, which require reliable temperature management for their products.
Demand for temperature-controlled logistics in the pharmaceutical industry
Regulatory changes impacting pharmaceutical shipping standards
Technological advancements in thermal insulation materials
Expansion into new geographic markets, particularly in Asia
Technological disruption from emerging insulation technologies
Regulatory changes affecting packaging standards in the pharmaceutical industry
Increased competition from low-cost manufacturers in Asia
Potential market share loss to companies with alternative temperature management solutions
Liquidity risk due to negative operating cash flow
Dependence on continued investment in R&D to maintain competitive edge
moderate - The company's performance is linked to industrial activity and consumer spending, particularly in the pharmaceutical sector, which can be sensitive to economic cycles.
Interest rates affect the company's cost of capital and financing for expansion projects, potentially impacting its growth trajectory and valuation multiples.
minimal - The company has a manageable debt level with a Debt/Equity ratio of 0.44, indicating limited reliance on credit.
growth - Investors looking for exposure to innovative industrial solutions and the expanding pharmaceutical logistics market.
high - The stock has shown significant price volatility, evidenced by a 1-year return of 166%.
